Payment overview · 2025
General Payments
$768.26
40 reported records · 14 companies
Healthcare provider profile · identity verified
Rani Anbarasu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DENTON, TX · NPI 1326252255
Verified facts
What the public records show
CMS Open Payments records show Rani Anbarasu, M.D. received $768.26 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.70 | 26.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.09 | 15.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.24 | 11.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.03 | 8.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $56.63 | 7.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.61 | 5.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.23 | 4.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.33 | 4.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.93 | 3.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.88 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.86 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.46 | 2.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $16.76 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.51 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $768.26 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.93 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.09 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.24 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.44 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.28 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
120 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 905 | 258 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 567 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 117 |
| Pravastatin Sodium | Pravastatin Sodium | 331 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 108 |
| Lisinopril | Lisinopril | 292 | 93 |
| Gabapentin | Gabapentin | 282 | 100 |
| Omeprazole | Omeprazole | 268 | 89 |
| Allopurinol | Allopurinol | 267 | 77 |
| Losartan Potassium | Losartan Potassium | 264 | 97 |
| Montelukast Sodium | Montelukast Sodium | 229 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 65 |
| Potassium Chloride | Potassium Chloride | 212 | 65 |
| Metformin Hcl Er | Metformin Hcl | 179 | 55 |
| Furosemide | Furosemide | 170 | 67 |
| Simvastatin | Simvastatin | 170 | 48 |
| Carvedilol | Carvedilol | 165 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 149 | 50 |
| Glimepiride | Glimepiride | 144 | 46 |
| Eliquis | Apixaban | 135 | 35 |
| Jardiance | Empagliflozin | 133 | 36 |
| Ezetimibe | Ezetimibe | 131 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 38 |
| Metformin Hcl | Metformin Hcl | 126 | 36 |
| Trazodone Hcl | Trazodone Hcl | 122 | 47 |
| Sertraline Hcl | Sertraline Hcl | 120 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 120 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 58 |
| Finasteride | Finasteride | 109 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 34 |
| Azithromycin | Azithromycin | 90 | 81 |
| Ibandronate Sodium | Ibandronate Sodium | 89 | 32 |
| Meloxicam | Meloxicam | 88 | 45 |
| Atenolol | Atenolol | 85 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 84 | 32 |
| Mirtazapine | Mirtazapine | 76 | 24 |
| Synthroid | Levothyroxine Sodium | 75 | 31 |
| Fenofibrate | Fenofibrate | 72 | 21 |
| Tramadol Hcl | Tramadol Hcl | 72 | 26 |
| Alprazolam | Alprazolam | 71 | 16 |
| Ozempic | Semaglutide | 71 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 68 | 19 |
| Farxiga | Dapagliflozin Propanediol | 67 | 21 |
| Spironolactone | Spironolactone | 66 | 19 |
| Prednisone | Prednisone | 63 | 52 |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 20 |
| Celecoxib | Celecoxib | 61 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 58 | 18 |
| Chlorthalidone | Chlorthalidone | 56 | 20 |
| Estradiol | Estradiol | 55 | 20 |
| Famotidine | Famotidine | 54 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 44 |
| Memantine Hcl | Memantine Hcl | 48 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 48 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Irbesartan | Irbesartan | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 15 |
| Torsemide | Torsemide | 41 | 16 |
| Folic Acid | Folic Acid | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 16 |
| Nystatin | Nystatin | 40 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 12 |
| Lovastatin | Lovastatin | 39 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Methylprednisolone | Methylprednisolone | 38 | 36 |
| Mounjaro | Tirzepatide | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 13 |
| Anastrozole | Anastrozole | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Prolia | Denosumab | 34 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Buspirone Hcl | Buspirone Hcl | 33 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Baclofen | Baclofen | 32 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Ramipril | Ramipril | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Nateglinide | Nateglinide | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Cephalexin | Cephalexin | 15 | 14 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Blisovi Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $768.26 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, OTEZLA, Ozempic, PROCLAIM, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, VOQUEZNA, VYEPTI, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error